Jiangjiang Zhu
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (17)
The incidence of colorectal cancer in young adults (age of diagnosis Significance: We investigated whether environmentally driven factors contribute to EOCRC. We observed accelerated epigenetic aging in EOCRC and epigenetic changes associated with chronic inflammation. Tumor immune cell abundances correlated more strongly with microbes in EOCRC than in AOCRC. These data suggest a dysregulation of the immune response in EOCRC, driving chronic inflammation and tissue aging.
Year:
2025
Relationship between microbes and immune cell composition. A, All microbe-genus level abundances (columns) correlated to the deconvolved immune cell abundances (rows), with the strength of the association and its direction indicated by color in the TCGA (top row) and ORIEN (bottom row) datasets. Spearman correlations between the deconvolved abundance of ( B ) activated mast cells or ( C ) neutrophils and microbes in both the TCGA and ORIEN datasets. Concordant associations (significant in both and in the same direction) are shown in green, with select taxa labeled. There were no microbes significantly anticorrelated with activated mast cells or neutrophils.
Year:
2025
Accelerated aging with epigenetic signatures in EOCRC. A, Heatmap was drawn with samples (patients) in the row and CpG sites (probes) in the column. The DNAm values range from 0.0 (completely unmethylated, blue) to 1.0 (completely methylated, red). B, The volcano plot demonstrated differential methylated sites (expressed as β values) between EOCRC and AOCRC groups. △β for each CpG site is defined as β value of (EOCRC – AOCRC). FDR-adjusted P P value P value C, Box plot showed the mean β value of patients with EOCRC and AOCRC was 0.46 ± 0.028 and 0.47 ± 0.027 ( P value = 0.13, two-sample t test), respectively. D, Box plots demonstrated the accelerated aging in EOCRC. The DNAm age acceleration (Δ = methylation age − chronologic age) in EOCRC and AOCRC for all samples is shown. The Δ EOCRC predicted by Horvath, Hannum, and PhenoAge models was 2.1, 18.4, and 32.8 years, respectively. The Δ AOCRC predicted by Horvath, Hannum, and PhenoAge was −14.2, 3.4, and 27.1 years, respectively, with P values of 7.89E−12, 1.48E−08, and 0.17, respectively.
Year:
2025
Intratumoral microbes do not show consistent differences in EOCRC. A, Venn diagram demonstrated partial overlap in microbes among three datasets. The abundances of observed genera that passed stringent quality and contamination filters are shown (ORIEN, n = 353 genera; TCGA, n = 357 genera; and 16S, n = 30 genera), with the best agreement between the two RNA-seq datasets. B, The Bray–Curtis dissimilarity plot showed that RNA-seq–derived microbes were most similar to 16S microbes from the same tumor (paired) and least similar to microbes from adjacent normal tissue from another person (unpaired). C, The comparison of the relative abundance of microbes between the 16S-based dataset and the RNA-seq–based datasets (ORIEN and TCGA). D–F, Volcano plots showed no consistent differences in microbes from RNA-seq–based (TCGA, ORIEN) or 16S-based datasets. No microbes passed the significance threshold in EOCRC. G–I, Effect sizes of the most significant taxa across the three analyses showed no similarities in the AOCRC-enriched microbes.
Year:
2025
Methylation signature validation through GE profiles in EOCRC. A, Integration of the differentially methylated sites with paired RNA-seq showed genes that vary in methylation and transcription. The threshold for the FDR-adjusted P values for differences is 0.05 (FDR P value ≤ 0.05). Highlighted genes in orange indicate significant hypomethylation and expression. B, The canonical pathways involved with DMGs in EOCRC have an FDR-adjusted P value C and D, Bubble chart of pathways based on DEGs in EOCRC from TCGA and ORIEN, highlighting those predicted by methylation alone. The color of the pathways is based on their z -score, and the size of the bubble is correlated with the number of genes from the dataset that overlap each pathway. E, Summary of the analyses to validate the differential methylation, with those supported by all three datasets indicated within the box.
Year:
2025
Colorectal cancer (CRC) is the second leading cause of cancer‐related mortality in the United States when considering both men and women. Colonoscopy remains the gold standard for CRC diagnosis but is invasive, costly, and requires extensive bowel preparation and sedation. Recent advancements in high throughput “omics” technologies may offer less invasive methods for CRC diagnosis through biomarker discovery. This study introduces a novel bioinformatics pipeline, PLS‐ANN‐DA (PANDA), combining partial least squares discriminant analysis (PLS‐DA) with an advanced artificial neural network (ANN) to improve CRC diagnosis and monitor disease progression. We analyzed metabolic alterations in CRC using a metabolomics data set of 626 CRC cases and 402 healthy controls (HC). Meanwhile, complementary transcriptomic data were also analyzed and integrated to further understand CRC metabolic dysregulations. By integrating metabolomics and transcriptomics analyses and establishing the biomarker discovery pipeline PANDA, significant metabolic pathway alterations were identified between CRC patients and healthy controls, with notable upregulation of multiple pathways in CRC. Meanwhile, we observed a downregulation of specific pathways, including purine metabolism and the tricarboxylic acid (TCA) cycle, associated with advanced tumor stages. The PANDA pipeline showed promising outcomes by effectively differentiating CRC from healthy states and providing insight into metabolic shifts occurring in advanced CRC stages. Genetic mutation‐associated metabolic changes were also discovered. Overall, this method has the potential for noninvasive CRC diagnostics and may serve as a valuable tool for understanding metabolic changes in cancer progression.
Year:
2025
Cancer has been marked by metabolic irregularities that fuel various aggressive activities such as rapid cell proliferation, evasion of the immune system, and spread to distant organs. Therefore, exploiting cancer metabolism for diagnosis, monitoring, or treatment has been extensively studied in the past couple of decades with various molecular and cellular techniques. More recently, investigating cancer diagnostics and treatments through advanced metabolomics has emerged, and these comprehensive approaches provide a holistic understanding of cancer metabolism, which supported the discovery of metabolic targets relevant across multiple cancer types and the development of more effective treatments. This study offers highlights of new knowledge on cancer metabolism enabled by recent metabolomics studies and their potential applications in aiding cancer research and predicting cancer treatment outcomes. Specifically, we discussed the use of advanced metabolomics in cancer metabolism, tumor microenvironment, and cancer immunotherapy studies to provide valuable insights that can shape future research efforts in the dynamic field of cancer metabolism research.
Year:
2024
Metabolomics and foodomics shed light on the molecular processes within living organisms and the complex food composition by leveraging sophisticated analytical techniques to systematically analyze the vast array of molecular features. The traditional feature-picking method often results in arbitrary selections of the model, feature ranking, and cut-off, which may lead to suboptimal results. Thus, a Multiple and Optimal Screening Subset (MOSS) approach was developed in this study to achieve a balance between a minimal number of predictors and high predictive accuracy during statistical model setup. The MOSS approach compares five commonly used models in the context of food matrix analysis, specifically bourbons. These models include Student’s t-test, receiver operating characteristic curve, partial least squares-discriminant analysis (PLS-DA), random forests, and support vector machines. The approach employs cross-validation to identify promising subset feature candidates that contribute to food characteristic classification. It then determines the optimal subset size by comparing it to the corresponding top-ranked features. Finally, it selects the optimal feature subset by traversing all possible feature candidate combinations. By utilizing MOSS approach to analyze 1406 mass spectral features from a collection of 122 bourbon samples, we were able to generate a subset of features for bourbon age prediction with 88% accuracy. Additionally, MOSS increased the area under the curve performance of sweetness prediction to 0.898 with only four predictors compared with the top-ranked four features at 0.681 based on the PLS-DA model. Overall, we demonstrated that MOSS provides an efficient and effective approach for selecting optimal features compared with other frequently utilized methods.
Year:
2024
Circos plot representation of the distribution of identified species and cancer types. The segment length for each cancer type is proportional to the ratio of the total number of detected species within that cancer type, and individual ribbons are linked to their respective species. The cancer types are abbreviated as COAD (colon adenocarcinoma), LUAD (lung adenocarcinoma), LUSC (lung squamous cell carcinoma), OtherCR (other colorectal cancer types not specified), OtherLung (other lung cancer types not specified), OtherPancreatic (other pancreatic cancer types not specified), PAAD (pancreatic adenocarcinoma), READ (rectum adenocarcinoma), SARC (sarcoma), SCLC (small cell lung cancer), SKCM (skin cutaneous melanoma), and THCA (thyroid carcinoma).
Year:
2024
Circos plot representation of the distribution of identified species and cancer types. The segment length for each cancer type is proportional to the ratio of the total number of detected species within that cancer type, and individual ribbons are linked to their respective species. The cancer types are abbreviated as COAD (colon adenocarcinoma), LUAD (lung adenocarcinoma), LUSC (lung squamous cell carcinoma), OtherCR (other colorectal cancer types not specified), OtherLung (other lung cancer types not specified), OtherPancreatic (other pancreatic cancer types not specified), PAAD (pancreatic adenocarcinoma), READ (rectum adenocarcinoma), SARC (sarcoma), SCLC (small cell lung cancer), SKCM (skin cutaneous melanoma), and THCA (thyroid carcinoma).
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (22)
Eric Singer
Professor
The Ohio State University Wexner Medical Center
Gregory Riedlinger
Rutgers Cancer Institute of New Jersey
Nicholas Denko
Professor
Ohio State University
Aik Choon Tan
Senior Director of Data Science
Huntsman Cancer Institute
Ning Jin
Associate Proffessor
Ohio State University
Martin D. McCarter
Professor
University of Colorado Anschutz Medical Campus
Carlos HF Chan
Emory University
Matthew Kalady
Professor
Ohio State University
John D. Carpten
City of Hope Comprehensive Cancer Center
Alexandra Ikeguchi
Associate Professor
The University of Texas MD Anderson Cancer Center
Rebecca Dodd
Assistant Professor
The University of Iowa
Gabriel Tinoco
Associate Professor of Medicine
Ohio State University
Anjun Ma
Assistant Professor
Ohio State University
Sheetal Hardikar
University of Utah
Qin Ma
Vice Chair for Research
Ohio State University
Yousef Zakharia
Mayo Clinic Arizona
Dan Spakowicz
Assistant Professor
The Ohio State University Comprehensive Cancer Center
Daniel W. Rosenberg
University of Connecticut Health Center
Xiaokui Mo
Research Scientist
Ohio State University
Ahmad Tarhini
Senior Member, Professor
H Lee Moffitt Cancer Center and Research Institute
Caroline Dravillas
Ohio State University
YunZhou Liu
Ohio State University
Make your next move.
Prepare your application
Review drafts before you send them.